ASH 2018 | ZUMA-1 update: durable survival in R/R DLBCL patients treated with axi-cel

Sattva Neelapu

Here, Sattva Neelapu, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the two-year follow-up of the ZUMA-1 study (NCT02348216) assessing axicabtagene ciloleucel (axi-cel) in relapsed/refractory, diffuse large B-cell lymphoma (DLBCL) patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Prof. Neelapu mentions that 51% of patients treated with axi-cel survived the two-year period, a fourfold increase compared to the historical median survival of six months.

Share this video